Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.The Lancet Oncology (impact factor: 22.59). 01/2005; 5(12):750-2. DOI:10.1016/S1470-2045(04)01652-3 pp.750-2
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.